These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 28167544

  • 1. Nanoliposomal Buparvaquone Immunomodulates Leishmania infantum-Infected Macrophages and Is Highly Effective in a Murine Model.
    da Costa-Silva TA, Galisteo AJ, Lindoso JA, Barbosa LR, Tempone AG.
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167544
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness of liposomal buparvaquone in an experimental hamster model of Leishmania (L.) infantum chagasi.
    Reimão JQ, Colombo FA, Pereira-Chioccola VL, Tempone AG.
    Exp Parasitol; 2012 Mar; 130(3):195-9. PubMed ID: 22281156
    [Abstract] [Full Text] [Related]

  • 3. Orally Bioavailable and Effective Buparvaquone Lipid-Based Nanomedicines for Visceral Leishmaniasis.
    Smith L, Serrano DR, Mauger M, Bolás-Fernández F, Dea-Ayuela MA, Lalatsa A.
    Mol Pharm; 2018 Jul 02; 15(7):2570-2583. PubMed ID: 29762040
    [Abstract] [Full Text] [Related]

  • 4. Targeting intracellular Leishmania (L.) infantum with nitazoxanide entrapped into phosphatidylserine-nanoliposomes: An experimental study.
    Pinto EG, Barbosa LRS, Mortara RA, Tempone AG.
    Chem Biol Interact; 2020 Dec 01; 332():109296. PubMed ID: 33096056
    [Abstract] [Full Text] [Related]

  • 5. In vivo antileishmanial activity and histopathological evaluation in Leishmania infantum infected hamsters after treatment with a furoxan derivative.
    de Almeida L, Passalacqua TG, Dutra LA, Fonseca JNVD, Nascimento RFQ, Imamura KB, de Andrade CR, Dos Santos JL, Graminha MAS.
    Biomed Pharmacother; 2017 Nov 01; 95():536-547. PubMed ID: 28866421
    [Abstract] [Full Text] [Related]

  • 6. Sertraline Delivered in Phosphatidylserine Liposomes Is Effective in an Experimental Model of Visceral Leishmaniasis.
    Romanelli MM, da Costa-Silva TA, Cunha-Junior E, Dias Ferreira D, Guerra JM, Galisteo AJ, Pinto EG, Barbosa LRS, Torres-Santos EC, Tempone AG.
    Front Cell Infect Microbiol; 2019 Nov 01; 9():353. PubMed ID: 31737574
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of lapachol on treatment of cutaneous and visceral leishmaniasis.
    Araújo IAC, de Paula RC, Alves CL, Faria KF, Oliveira MM, Mendes GG, Dias EMFA, Ribeiro RR, Oliveira AB, Silva SMD.
    Exp Parasitol; 2019 Apr 01; 199():67-73. PubMed ID: 30797783
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis.
    Soyer TG, Mendonça DVC, Tavares GSV, Lage DP, Dias DS, Ribeiro PAF, Perin L, Ludolf F, Coelho VTS, Ferreira ACG, Neves PHAS, Matos GF, Chávez-Fumagalli MA, Coimbra ES, Pereira GR, Coelho EAF, Antinarelli LMR.
    Exp Parasitol; 2019 Apr 01; 199():30-37. PubMed ID: 30817917
    [Abstract] [Full Text] [Related]

  • 9. Protection mediated by chemokine CXCL10 in BALB/c mice infected by Leishmania infantum.
    Figueiredo WME, Viana SM, Alves DT, Guerra PV, Coêlho ZCB, Barbosa HS, Teixeira MJ.
    Mem Inst Oswaldo Cruz; 2017 Aug 01; 112(8):561-568. PubMed ID: 28767981
    [Abstract] [Full Text] [Related]

  • 10. 15d-Prostaglandin J2 induced reactive oxygen species-mediated apoptosis during experimental visceral leishmaniasis.
    Vishwakarma P, Parmar N, Yadav PK, Chandrakar P, Kar S.
    J Mol Med (Berl); 2016 Jun 01; 94(6):695-710. PubMed ID: 26830627
    [Abstract] [Full Text] [Related]

  • 11. An effective in vitro and in vivo antileishmanial activity and mechanism of action of 8-hydroxyquinoline against Leishmania species causing visceral and tegumentary leishmaniasis.
    Costa Duarte M, dos Reis Lage LM, Lage DP, Mesquita JT, Salles BC, Lavorato SN, Menezes-Souza D, Roatt BM, Alves RJ, Tavares CA, Tempone AG, Coelho EA.
    Vet Parasitol; 2016 Feb 15; 217():81-8. PubMed ID: 26827866
    [Abstract] [Full Text] [Related]

  • 12. Nanoliposomal artemisinin for the treatment of murine visceral leishmaniasis.
    Want MY, Islammudin M, Chouhan G, Ozbak HA, Hemeg HA, Chattopadhyay AP, Afrin F.
    Int J Nanomedicine; 2017 Feb 15; 12():2189-2204. PubMed ID: 28356736
    [Abstract] [Full Text] [Related]

  • 13. Mixed formulation of conventional and pegylated liposomes as a novel drug delivery strategy for improved treatment of visceral leishmaniasis.
    Azevedo EG, Ribeiro RR, da Silva SM, Ferreira CS, de Souza LE, Ferreira AA, de Oliveira E Castro RA, Demicheli C, Rezende SA, Frézard F.
    Expert Opin Drug Deliv; 2014 Oct 15; 11(10):1551-60. PubMed ID: 24962630
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and tolerability of oleylphosphocholine (OlPC) in a laboratory model of visceral leishmaniasis.
    Fortin A, Hendrickx S, Yardley V, Cos P, Jansen H, Maes L.
    J Antimicrob Chemother; 2012 Nov 15; 67(11):2707-12. PubMed ID: 22782488
    [Abstract] [Full Text] [Related]

  • 15. Oral administration of buparvaquone nanostructured lipid carrier enables in vivo activity against Leishmania infantum.
    Monteiro LM, Löbenberg R, Barbosa EJ, de Araujo GLB, Sato PK, Kanashiro E, de Araujo Eliodoro RH, Rocha M, de Freitas VLT, Fotaki N, Bou-Chacra NA.
    Eur J Pharm Sci; 2022 Feb 01; 169():106097. PubMed ID: 34910988
    [Abstract] [Full Text] [Related]

  • 16. Hemisynthetic trifluralin analogues incorporated in liposomes for the treatment of leishmanial infections.
    Carvalheiro M, Esteves MA, Santos-Mateus D, Lopes RM, Rodrigues MA, Eleutério CV, Scoulica E, Santos-Gomes G, Cruz ME.
    Eur J Pharm Biopharm; 2015 Jun 01; 93():346-52. PubMed ID: 25936854
    [Abstract] [Full Text] [Related]

  • 17. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections.
    Miguel DC, Zauli-Nascimento RC, Yokoyama-Yasunaka JK, Katz S, Barbiéri CL, Uliana SR.
    J Antimicrob Chemother; 2009 Feb 01; 63(2):365-8. PubMed ID: 19095684
    [Abstract] [Full Text] [Related]

  • 18. Histamine H1-receptor antagonists against Leishmania (L.) infantum: an in vitro and in vivo evaluation using phosphatidylserine-liposomes.
    Pinto EG, da Costa-Silva TA, Tempone AG.
    Acta Trop; 2014 Sep 01; 137():206-10. PubMed ID: 24905294
    [Abstract] [Full Text] [Related]

  • 19. Cyclobenzaprine Raises ROS Levels in Leishmania infantum and Reduces Parasite Burden in Infected Mice.
    Cunha-Júnior EF, Andrade-Neto VV, Lima ML, da Costa-Silva TA, Galisteo Junior AJ, Abengózar MA, Barbas C, Rivas L, Almeida-Amaral EE, Tempone AG, Torres-Santos EC.
    PLoS Negl Trop Dis; 2017 Jan 01; 11(1):e0005281. PubMed ID: 28045892
    [Abstract] [Full Text] [Related]

  • 20. Generation of luciferase-expressing Leishmania infantum chagasi and assessment of miltefosine efficacy in infected hamsters through bioimaging.
    Reimão JQ, Oliveira JC, Trinconi CT, Cotrim PC, Coelho AC, Uliana SR.
    PLoS Negl Trop Dis; 2015 Feb 01; 9(2):e0003556. PubMed ID: 25679212
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.